ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

BMEA Biomea Fusion Inc

11.16
0.00 (0.00%)
Pre Market
Last Updated: 07:34:41
Delayed by 15 minutes

Period:

Draw Mode:

Volume 6
Bid Price 10.86
Ask Price 11.38
News -
Day High

Low
8.125

52 Week Range

High
43.69

Day Low
Company Name Stock Ticker Symbol Market Type
Biomea Fusion Inc BMEA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 11.16 07:34:41
Open Price Low Price High Price Close Price Prev Close
11.16
Trades Volume Avg Volume 52 Week Range
2 6 - 8.125 - 43.69
Last Trade Time Type Quantity Stock Price Currency
08:00:00 5 $ 11.25 USD

Biomea Fusion (BMEA) Options Flow Summary

Overall Flow

Bearish

Net Premium

-30k

Calls / Puts

50.00%

Buys / Sells

50.00%

OTM / ITM

50.00%

Sweeps Ratio

0.00%

Biomea Fusion Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
398.48M 35.71M - 0 -81.83M -2.29 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Biomea Fusion News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No BMEA Message Board. Create One! See More Posts on BMEA Message Board See More Message Board Posts

Historical BMEA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week13.2313.6610.9511.90966,730-2.07-15.65%
1 Month16.8416.9710.9513.281,024,184-5.68-33.73%
3 Months17.0020.2110.9515.901,060,799-5.84-34.35%
6 Months11.2222.748.12515.001,149,651-0.06-0.53%
1 Year26.8043.698.12518.75902,872-15.64-58.36%
3 Years17.2643.692.8418.51441,008-6.10-35.34%
5 Years20.0043.692.8418.51443,880-8.84-44.20%

Biomea Fusion Description

Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.

Your Recent History

Delayed Upgrade Clock